JPMorgan assumed coverage of Adaptive Biotechnologies with an Overweight rating and $15 price target. The analyst maintained the firm’s current rating, price target, and estimates.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADPT:
- Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
- Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
- ‘Too Cheap to Ignore’: Cathie Wood Snaps Up These 2 Stocks Under $10
- Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology